Drugs / KK-LC-1 TCR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05483491 | Sep 2022 → Sep 2026 overdue | breast cancer, cervical cancer, gastric cancer, lung cancer | Christian Hinrichs | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KK-LC-1 TCR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05483491 ↗ |
| Modality | Cell therapy | “KK-LC-1 TCR-T cells are autologous T cells that are genetically engineered” NCT05483491 ↗ |
| Route | Intravenous | “KK-LC-1 TCR-T cells will be administered as a single intravenous infusion.” NCT05483491 ↗ |